ALung brings in $12M to move forward with approval of its artificial lung
ALung Technologies Inc. has secured $12 million from investors. The Pittsburgh-based medical device company is working toward U.S. regulatory approval of its artificial lung.
ALung Technologies Inc. has secured $12 million from investors. The Pittsburgh-based medical device company is working toward U.S. regulatory approval of its artificial lung.
ALung Technologies Inc. has raised a $10 million series B round in preparation for a product launch of its Hemolung oxygen-delivery device in Germany this year, the Pittsburgh Tribune-Review is reporting. MedCity News reported back in December that the medical device company had already raised $6.6 million and filed for the CE Mark. The Hemolung […]
ALung Technologies is targeting a $10 million series B round of investment for the European launch of its respiratory assistance system that removes carbon dioxide from a patient’s blood while directly infusing the blood with oxygen. The company is already most of the way there, having just closed on $6.6 million and having received commitments […]
More than 100 angel investors helped ALung Technologies Inc. in Pittsburgh, Pennsylvania, to a $14 million fundraising round, according to Pop City. ALung will use the latest investor capital to pay for ongoing clinical trials of its Hemolung Respiratory Assist System -- a kind of artificial lung that removes carbon dioxide directly from a patient's blood while infusing it with oxygen.
Respiratory-assistance company ALung Technologies Inc. has added $2.8 million in equity to what it hopes will be a $10 million round of investment funding, according to a Securities and Exchange Commission filing. The latest fundraise brings to $6.1 million the amount that ALung has raised since February. The funding includes contributions from 22 investors, according […]
ALung Technologies Inc. has raised $3.3 million in equity as part of an intended $10 million offering. The company is developing a respiratory-assistance system it calls the Hemolung, which delivers oxygen directly into the blood using a catheter into the femoral or jugular vein.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
The company is developing its Hemolung System, which delivers oxygen directly into the blood using a catheter into the jugular vein. Later this year it will start a five-patient human trial in India and a 20-patient trial in Germany.